- Report
- May 2024
- 269 Pages
Global
From €5237EUR$5,450USD£4,503GBP
- Report
- December 2023
- 116 Pages
Global
From €4324EUR$4,500USD£3,718GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£413GBP
- Report
- January 2019
- 35 Pages
Global
From €961EUR$1,000USD£826GBP
- Drug Pipelines
- March 2021
Global
From €1922EUR$2,000USD£1,652GBP
- Report
- April 2023
- 160 Pages
Global
From €5764EUR$5,999USD£4,956GBP
Amitiza is a prescription medication used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It is a chloride channel activator that works by increasing fluid secretion in the intestines, which helps to soften stools and increase bowel movements. It is available in 8 mcg and 24 mcg capsules. Amitiza is the only FDA-approved medication for CIC and IBS-C that works by increasing fluid secretion in the intestines.
The Amitiza market is a subset of the larger gastrointestinal drugs market. It is composed of medications used to treat a variety of gastrointestinal conditions, including CIC and IBS-C. These medications are typically prescribed by gastroenterologists and other healthcare professionals.
Some companies in the Amitiza market include Allergan, Ironwood Pharmaceuticals, and Takeda Pharmaceuticals. Show Less Read more
